8 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 8 of 8 clinical reviews.
A timeline of FDA label changes for Lantus (insulin glargine) from 2020 through 2026, including safety language revisions, biosimilar interchangeability developments, and what remains unverified in public reporting on this topic.
A complete regulatory guide to Lantus (insulin glargine) compounding legal status, FDA approval history, label requirements, and safety data, prepared by the HealthRX.com Editorial Team.
A detailed comparison of how the FDA and EMA approved, labeled, and monitor insulin glargine (Lantus), including biosimilar pathways, cancer signal investigations, and post-market surveillance differences.
A clinical review of FDA Adverse Event Reporting System (FAERS) data for Lantus (insulin glargine), covering hypoglycemia trends, cancer concerns resolved by ORIGIN, and ongoing pharmacovigilance signals.
A full regulatory history of Lantus (insulin glargine) including FDA approval dates, label changes, biosimilar entries, and post-market safety data. prepared by the HealthRX.com Editorial Team.
A comprehensive review of insulin glargine (Lantus) global regulatory status, FDA approval history, prescribing label details, and post-market safety surveillance findings.
A clinical review of Lantus (insulin glargine) patent litigation, FDA approval history, label evolution, and the legal battles that delayed biosimilar competition for over a decade.
A clinical review of the insulin glargine pipeline, next-generation basal insulins, biosimilars, and post-market regulatory updates for Lantus (glargine U-100).